Guggenheim Reiterates Buy on Neumora Therapeutics, Maintains $14 Price Target
Neumora Therapeutic +7.50%
Neumora Therapeutic NMRA | 2.15 | +7.50% |
Guggenheim analyst Yatin Suneja reiterates Neumora Therapeutics (NASDAQ:
NMRA) with a Buy and maintains $14 price target.
